PT - JOURNAL ARTICLE AU - Patrick Collier AU - Muzna Hussain AU - Zoran B. Popovic AU - Brian P. Griffin TI - Cardiac surveillance for anti-HER2 chemotherapy AID - 10.3949/ccjm.88a.19150 DP - 2021 Feb 01 TA - Cleveland Clinic Journal of Medicine PG - 110--116 VI - 88 IP - 2 4099 - http://www.ccjm.org/content/88/2/110.short 4100 - http://www.ccjm.org/content/88/2/110.full SO - Cleve Clin J Med2021 Feb 01; 88 AB - Surveillance of left ventricular function, part of current US Food and Drug Administration recommendations for anti-human epidermal growth factor receptor 2 (anti-HER2) chemotherapy, is based on historical data involving patients who received concomitant anthracycline therapy, a key enhancer of cardiac risk. More recent anti-HER2 treatment data suggest that cardiotoxicity detected by screening is rare and usually benign for patients who do not have cardiovascular risk factors and are not taking an anthracycline. Because of the burden of repetitive echocardiography required for surveillance and the risk of false-positive results, potentially leading to discontinuing lifesaving treatment, we advocate for a more focused cardiac surveillance strategy.